Navigation Links
New Treatment Rivals Chemotherapy For Lymphoma, Study Finds

icular non-Hodgkin's lymphoma after other treatments have failed. The newly published research involves Bexxar as a first-line treatment for this disease.

Non-Hodgkin's lymphoma, the nation's sixth leading cause of cancer death, is a cancer of the lymph system, which is part of the immune system. Lymphoma spreads easily through the lymph system and the bloodstream and consequently tends to be widespread when it is diagnosed. Traditional treatment often involves intensive chemotherapy, or a combination of chemotherapy and the monoclonal antibody rituximab. These treatments are usually given every three weeks over a span of up to six months and can cause many unpleasant side effects, including nausea, hair loss and infections.

Follicular lymphoma is the second most common type of non-Hodgkin's lymphoma and is not considered to be curable using these traditional treatments; even after patients initially have a response to treatment, the disease almost always comes back and becomes more difficult to treat.

Bexxar, whose chemical name is tositumomab and iodine I 131 tositumomab, combines an antibody that seeks out cancer cells, and a radioactive form of the element iodine. When injected, it travels like a guided missile through the bloodstream to bind to a protein found on the surface of the cancerous cells. The radiation zaps these malignant cells with minimal exposure to normal tissues.

With the Bexxar therapeutic regimen, a patient receives an injected test dose of radioactive Bexxar to determine how that patient's body processes the tagged antibody. Nuclear medicine scans are used to assess how quickly Bexxar reaches the tumor and how quickly the radiation disappears from the patient's body. One to two weeks after that initial dose, the patient then receives a custom-tailored therapeutic dose, and therapy is considered complete. The most common side effect is a temporary lowering of blood counts several weeks after the treatment. There
'"/>

Source:University Of Michigan Health System


Page: 1 2 3

Related biology news :

1. Discovery Could Lead To Novel Approaches In HIV Treatment
2. Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments
3. Effective Cancer Treatments Follow The Clock
4. Protein Discovery Could Unlock The Secret To Better TB Treatment
5. Natural Killers Could Lead to New Hepatitis Treatments
6. FDA Approves New Treatment for Chronic Hepatitis B
7. Study Finds Moderate Hypothermia A Safe Treatment For Traumatic Brain Injury In Kids
8. Drug Offers Alternative to Surgical Treatment After Miscarriage
9. Treatments have same target, different responses for lung cancer patients with genetic mutation
10. Minimally Invasive Cancer Treatments Highlighted
11. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
Post Your Comments: